Edition:
United Kingdom

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

23.29USD
20 Sep 2018
Change (% chg)

$1.39 (+6.35%)
Prev Close
$21.90
Open
$22.18
Day's High
$23.87
Day's Low
$22.18
Volume
82,610
Avg. Vol
42,916
52-wk High
$25.60
52-wk Low
$7.51

Chart for

About

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $131.52
Shares Outstanding(Mil.): 16.06
Dividend: --
Yield (%): --

Financials

  GTXI.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.71 -- --
ROI: -196.34 1.78 14.61
ROE: -196.34 3.27 16.33

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million (75.5 million pounds) deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

30 May 2018

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

30 May 2018

Deutsche Boerse beefs up forex business with $100 mln buy

BERLIN, May 30 Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

30 May 2018

BRIEF-GTX Announces Early Completion Of Patient Enrollment In The Astrid Trial

* GTX ANNOUNCES EARLY COMPLETION OF PATIENT ENROLLMENT IN THE ASTRID TRIAL, A PHASE 2 CLINICAL TRIAL OF ENOBOSARM IN STRESS URINARY INCONTINENCE

09 Apr 2018

Earnings vs. Estimates